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ORIGINAL ARTICLE
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ABSTRACT
In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in
progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents
were administered until disease progression; the EU label for Vd, however, stipulates a max-
imum of eight treatment cycles. Here, matching-adjusted treatment comparison was used to
compare efficacy of Kd56 with Vd, if Vd was administered for 8 cycles (Vd-8). Data from
ENDEAVOR and CASTOR trials (which compared daratumumab, bortezomib, and dexamethasone
with Vd-8) were used. Hazard ratios of PFS were estimated for Vd vs. Vd-8 and Kd vs. Vd-8. For
cycles 1–8, risk reduction in PFS for Kd56 vs. Vd-8 was equal to that estimated in ENDEAVOR
(HR: 0.53; 95% CI 0.44–0.65). Beyond eight cycles, risk reduction in PFS for Kd56 and Vd-8 was
estimated to be 60% (HR: 0.40; 95% CI 0.26–0.63). The analysis suggested that PFS benefit of
Kd56 over Vd increases when Vd is given for eight cycles only.
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The management of patients with multiple myeloma
(MM) has evolved dramatically over the past decade
owing to the introduction of more effective agents,
such as proteasome inhibitors and immunomodulatory
drugs [1,2]. More recently, monoclonal antibodies,
such as elotuzumab and daratumumab, and the his-
tone deacetylase inhibitor, panobinostat, have also
been approved [3–5]. Among proteasome inhibitors,
bortezomib (V) was the first agent to gain approval
for the treatment of MM [6]. The combination of dexa-
methasone and bortezomib (Vd) has been established
as a key regimen in the treatment of relapsed and/or
refractory MM (RRMM) [7–9].
Carfilzomib (K) is a next-generation proteasome
inhibitor that irreversibly binds to the proteasome, thus
resulting in more sustained inhibition than with the
reversible proteasome inhibitor V [9,10]. Carfilzomib is
approved in Europe for use in combination with dexa-
methasone (Kd56; K administered at an ultimate dose
of 56mg/m2), or with lenalidomide and dexamethasone
(KRd; K administered at a dose of 27mg/m2) for the
treatment of adults patients with MM who have
received at least one prior therapy [11,12]. The approval
of Kd56 was based on findings from the pivotal phase 3
randomized, controlled trial ENDEAVOR (NCT01568866),
a head-to-head comparison of Kd56 with Vd in patients
with RRMM. In order to have a direct head-to-head
comparison that was not biased by a protocol-defined
duration of treatment, Kd56 was compared with Vd
under the same treatment schedule, that is: until dis-
ease progression, withdrawal of consent, or unaccept-
able toxicity [13,14]. Thus, in ENDEAVOR, the median
(range) of Vd treatment duration was eight (5.0–15.0)
cycles, with 25% of patients receiving 15 cycles. This is
different from the treatment schedule in the
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bortezomib summary of product information and in
other clinical trials where Vd is generally administered
according to the European label, that is, for up to eight
cycles only [15].
In the ENDEAVOR trial, Kd56 was superior to Vd for
the primary outcome of progression-free survival
(PFS), with 18.7 months vs. 9.4 months median PFS for
Kd56 and Vd, respectively (hazard ratio (HR) 0.53; 95%
confidence interval (CI) 0.44, 0.65, p< .0001) [13].
ENDEAVOR also demonstrated a significant improve-
ment in overall survival (OS) for Kd56 over Vd (median
OS 47.6 months vs. 40.0 months, HR 0.79; 95% CI 0.65,
0.96; p¼.010) [14]. Adverse drug reactions were more
frequently reported in patients who were receiving
Kd56 than in those who were receiving Vd, including
hypertension and cardiac failure. In contrast, the num-
ber of patients with peripheral neuropathy was signifi-
cantly lower in the Kd56 group than in the Vd group
[13,14]. It has been demonstrated that Kd56 is gener-
ally well tolerated and has a favorable benefit–risk
profile [16].
The present analysis aims to characterize the clin-
ical benefits of Kd56 vs. Vd by estimating the differ-
ence in efficacy and safety between Kd56 when given
until disease progression and Vd administered for up
to eight cycles as per the EU label. In the absence of
direct head-to-head comparative data between Kd56
and Vd-8, this analysis was based on matching-
adjusted indirect treatment comparisons (MAIC) using
data from the ENDEAVOR trial and the phase 3
CASTOR trial, which compared daratumumab, bortezo-
mib, and dexamethasone (DVd) with Vd-8 [17,18].
Materials and methods
Data
For the efficacy analysis, PFS data for Kd56 and Vd
(until progression) from ENDEAVOR, and for Vd-8 from
CASTOR (NCT02136134) were used. PFS was the pri-
mary outcome in both trials, and data from the lon-
gest published follow-up times were selected for
inclusion in the analysis. In ENDEAVOR, the assessment
of progression was based on the findings of an inde-
pendent review committee at the first prespecified
interim analysis, data cutoff 10 November 2014
(median follow-up 11.1 months (Vd) and 11.9 months
(Kd56)) [13]. In CASTOR, the assessment of progression
was based on a computerized algorithm and updated
safety and efficacy data, cutoff 30 August 2017
(median follow-up 26.9 months) [18]. For the safety
analysis of Kd56 vs. Vd-8, treatment-emergent adverse
event (TEAE) data observed with Kd56 and Vd in
ENDEAVOR were used (data cutoff 19 July 2017) [19].
ENDEAVOR and CASTOR study designs, patients,
and treatments
The study designs and participant information of the
ENDEAVOR [13] and CASTOR [17,20] trials have been
described previously. In brief, both studies included
adult patients with RRMM who had received one to
three (ENDEAVOR) or at least one (CASTOR) previous
line of therapy, who had achieved at least a partial
response to a previous line of therapy, and who had
adequate renal, hematological, and hepatic function.
In ENDEAVOR, patients were randomized (1:1) to
receive Kd56 (n¼ 464) or Vd (n¼ 465), administered
during 28-day (Kd56) or 21-day (Vd) cycles [13]. In
CASTOR, patients were randomized (1:1) to receive
DVd (n¼ 251) or Vd-8 (n¼ 247), administered during
21-day cycles as described previously [17]. Treatment
cycles were repeated eight times; in the DVd group,
daratumumab was continued after cycle 8, until pro-
gressive disease [17]. Patients in the ENDEAVOR and
CASTOR trials provided written informed consent, and
the trials were conducted in accordance with the prin-
ciples of the Declaration of Helsinki and the
International Conference on Harmonization Good
Clinical Practice guidelines.
Efficacy analyses
PFS outcomes with Kd56 and Vd-8 were compared
using a three-step modeling approach (Figure 1). In
the first step, to minimize any confounding bias owing
to observed differences across trial populations,
patients receiving Vd in ENDEAVOR and patients
receiving Vd-8 in CASTOR were matched for observed
baseline characteristics using MAIC [21]. In the base
case analysis, among all available variables, those con-
sidered to be predictive and prognostic factors for PFS
and OS were selected for the matching. This approach
is in agreement with the methods guide issued by the
National Institute for Health and Care Excellence for
population-adjusted indirect treatment comparisons
[22]. The selected variables reflected disease character-
istics and treatment history, and were generally con-
sistent with validated prognostic markers currently
used in stratifying patients into different risk groups
[23,24]. Details of the variable selection process have
been reported previously [25,26]. Table 1 presents an
overview of parameters used for the MAICs.
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Table 1. Baseline characteristics of patients receiving Vd in ENDEAVOR and Vd-8 in CASTOR.
Vd Vd Vd-8
ENDEAVOR ENDEAVOR CASTOR
(before matching) (after matching)a
(n¼ 465) (n¼ 378)b (n¼ 247)
Age, n (%)
<65 years 210 (45.2%) 191 (50.6%) 125 (50.6%)
65–74 years 189 (40.6%) 133 (35.2%) 87 (35.2%)
75þ years 66 (14.2%) 54 (14.2%) 35 (14.2%)
Sex, n (%)
Male 229 (49.2%) 184 (48.6%) 147 (59.5%)
International Staging System, n (%)c
Stage 1 204 (44.1%) 147 (38.9%) 96 (38.9%)
Stage 2 151 (32.5%) 153 (40.5%) 100 (40.5%)
Stage 3 109 (23.4%) 78 (20.6%) 51 (20.6%)
Baseline creatinine clearance >60mL/min, n (%) 297(63.9%) 264 (70.0%) 163 (70.0%)d
Type of multiple myeloma
IgG 284 (61.1%) 230 (60.9%) 138 (55.9%)
Other 181 (38.9%) 148 (39.1%) 109 (44.1%)
Time since diagnosis in years, median 3.61 2.92 3.72
Patients with time since diagnosis 3.72 years (%) 47.6% 50.0% 50%
Number of prior therapies, n (%)
1 232 (49.9%) 173 (45.7%) 113 (45.7%)
2 145 (31.2%) 113 (30.0%) 74 (30.0%)
3þ 87 (18.9%) 92 (24.3%) 60 (24.3%)
Prior bortezomib, n (%) 252 (54.2%) 251 (66.4%) 164 (66.4%)
Prior IMID, n (%) 348(74.8%) 303 (80.2%) 198 (80.2%)
Prior lenalidomide 177 (38.1%) 155 (41.1%) 120 (48.6%)
Prior PIþ IMID, n (%) 167 (35.9%) 189 (50.1%) 129 (52.2%)
Prior stem cell transplantation, n (%) 272 (58.5%) 228 (60.3%) 149 (60.3%)
Refractory to last prior therapy, n (%) 188 (40.4%) 130 (34.4%) 85 (34.4%)
Cytogenetic profile, n (%)
Standard risk 291 (62.6%) 233 (61.7%) 135 (54.7%)
High risk 113 (24.3%) 93 (24.5%) 51 (20.6%)
Missing 61 (13.1%) 52 (13.8%) 61 (24.7%)
IMID: immunomodulatory imide drugs; PI: proteasome inhibitor; Vd: bortezomib and dexamethasone.
aPatients receiving Vd in ENDEAVOR were matched to patients receiving Vd-8 in CASTOR based on observed baseline characteristics
using matching-adjusted indirect treatment comparison methodology. Base case matching analysis; the following variables were
used for the matching: age (65, 75, other), time from diagnosis, International Staging System (2, 3, other), creatinine clearance
(>60mL/min, other), number of prior therapies (1, 2, other), prior stem cell transplantation (yes, no), prior bortezomib (yes, no),
prior IMID (yes, no), and refractory to last prior therapy (yes, no).
bSample size was calculated as the sum of weights.
cISS measured at the start of treatment was used for matching.
dBased on 233 evaluable patients.
ENDEAVOR Vd patients were matched to average baseline characteristics 
of CASTOR Vd-8 patients using matching-adjusted indirect comparison 
methodology.
Matching 
1. Virtual patient-level data were constructed for Vd-8 in CASTOR.
2. A piecewise Cox regression model was fitted to the matched ENDEAVOR 
 Vd data and the reconstructed CASTOR Vd-8 data using 8 cycles as 
 cutoff date.
3. The increased PFS risk due to stopping Vd treatment after 8 cycles vs. 
 continuing Vd treatment beyond 8 cycles until progression was assessed 







After adjusting Vd-8 for patient selection criteria, observed, and unobserved 
differences between CASTOR and ENDEAVOR, an overall HR was estimated 




Figure 1. Summary of the stepwise modeling approach. HR: hazard ratio; Kd56: carfilzomib and dexamethasone; Vd: bortezomib
and dexamethasone; Vd-8: bortezomib and dexamethasone given until eight cycles.
KD56 VS. 8 CYCLES OF VD IN ENDEAVOR 39
In the second step, in the absence of access to
patient-level PFS data from the CASTOR trial, the pub-
lished Kaplan–Meier curves were digitized to generate
virtual patient-level CASTOR data that replicated the
Kaplan–Meier curves [27]. Then, a piecewise Cox
regression model was fitted to the matched
ENDEAVOR Vd data and CASTOR Vd-8 data. In the
piecewise Cox model, the cutoff date was determined
at 24 weeks (corresponding to eight cycles of Vd). This
model specification allowed separate HRs to be esti-
mated for the first eight cycles, and for the treatment
time beyond cycle 8. The HR for the first period cap-
tured all unobserved heterogeneity in baseline charac-
teristics and between-trial differences between the
matched PFS of ENDEAVOR Vd and the PFS of
CASTOR Vd-8 (i.e. visually, the difference between the
matched Vd and the Vd-8 PFS curves during the first
eight cycles). The HR estimated for the period beyond
eight cycles captured both unobserved heterogeneity
and the impact of stopping Vd after eight cycles.
Comparing these two HRs allowed the impact of
unobserved heterogeneity to be quantified and subse-
quently the net impact of stopping Vd after eight
cycles in ENDEAVOR to be quantified.
In the third step, adjusting for the between-trial dif-
ferences in terms of patient selection criteria and
observed baseline patient characteristics, as well as for
unobserved differences between Vd-8 in CASTOR and
Vd in ENDEAVOR, an overall HR was estimated for
Kd56 vs. Vd-8 capturing the difference in the risk of
progression or death during the first eight cycles and
beyond eight cycles.
To assess the robustness of the results, three scen-
ario analyses were explored: PFS for Vd in ENDEAVOR
truncated at 16 months (i.e. where the number of
patients at risk decreased below 5%), all available vari-
ables used for the matching, and no matching.
In addition, to assess whether continuing treatment,
in particular Vd treatment, until progression leads to
deeper responses over time than stopping treatment
after eight cycles, cumulative proportions of patients
in ENDEAVOR with a complete response (CR) or better,
or with a very good partial response (VGPR) or better
(for definitions of CR and VGPR, see [13]) were calcu-
lated for Kd56 and Vd from the start of the treatment.
Safety analyses
TEAEs (coded using MedDRA version 20.0) were ana-
lyzed based on the Kd56 and Vd safety data observed
in ENDEAVOR [19]. For patients who were receiving
Kd56, and for those receiving Vd for up to eight
cycles, TEAEs with an onset date from the first dose
until 30 days after the last dose of any study drug
were included in the analysis. For patients who contin-
ued Vd beyond cycle 8, TEAEs with an onset date
from cycle 9 to the last dose of any study drug were
not included. Analysis of TEAEs included crude inci-
dence proportions and exposure-adjusted incidences
per treatment group; Kd56/Vd-8 exposure-adjusted
incidence ratios and associated 95% CI were also cal-
culated using the Poisson log-linear models.
Results
Efficacy analyses
To estimate the impact of stopping Vd after eight
cycles on PFS, as a first step, patients who were
receiving Vd in ENDEAVOR were matched to the base-
line characteristics of those receiving Vd-8 in CASTOR.
The observed baseline characteristics of patients
receiving Vd in ENDEAVOR (n¼ 465) [13] and those
receiving Vd-8 in CASTOR (n¼ 247) [18,20] have been
published previously and are summarized in Table 1.
In both trials, the median age was 64–65 years,
46–50% had received one line of prior therapy, and
50–54% had received two or more lines of prior ther-
apy. Patients in the CASTOR trial had slightly more
advanced disease (61% with International Staging
System (ISS) scores  2) than those in ENDEAVOR
(56% with ISS scores 2). Matching for observed base-
line characteristics between the two trial populations
meant that differences were effectively eliminated
(Table 1).
After matching for observed baseline characteristics,
a difference in PFS (up to and beyond eight cycles)
was still evident between patients who were receiving
Vd in ENDEAVOR and Vd-8 in CASTOR (Figure 2). This
difference in PFS could be attributed to the unob-
served heterogeneity in baseline characteristics, to
between-trial heterogeneity that cannot be adjusted
for by matching, and to stopping Vd after eight cycles.
To assess the net impact of stopping Vd after eight
cycles, the follow-up period was divided into two parts
comprising cycles 1–8 and cycle 9 or more, respect-
ively. For the period of cycles 1–8, during which any
difference in PFS between the matched ENDEAVOR Vd
and CASTOR Vd patients could be attributed to unob-
served heterogeneity, the HR of PFS for ENDEAVOR Vd
vs. CASTOR Vd was 1.36 (95% CI 1.01, 1.81). For the
period of cycle 9 or more, during which a difference
in PFS between the matched ENDEAVOR Vd and
CASTOR Vd patients could be due to unobserved het-
erogeneity and the difference in Vd treatment
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duration, the HR of PFS for Vd ENDEAVOR vs. Vd
CASTOR was 1.79 (95% CI 1.36, 2.34). The ratio
between the two HRs provides an estimate of the net
impact on PFS of stopping Vd treatment after eight
cycles; thus, stopping Vd after eight cycles was esti-
mated to increase the risk of progression or death by
32% compared with Vd treatment until progression
(HR: 1.32; 95% CI 0.89, 1.96). The difference in PFS
between Kd56 and Vd-8 was estimated, assuming Vd
would have been stopped after eight cycles. For cycles
1–8, the risk reduction in PFS for Kd56 vs. Vd-8 cycles
was equal to that estimated for Kd56 vs. Vd in
ENDEAVOR (HR: 0.53; 95% CI 0.44, 0.65) [13]. Beyond
eight cycles, the risk reduction in PFS for Kd56 and
Vd-8 was estimated to be 60% (HR: 0.40; 95% CI 0.26,
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Figure 2. Impact on PFS of stopping Vd after eight cycles vs. continuing until progression. The HRs of PFS for the periods of
cycles 1–8 cycles and cycles 9þ were estimated using a piecewise Cox regression model fitted to CASTOR-matched ENDEAVOR Vd
data and reconstructed CASTOR Vd data. Vd cycle length was 21 days. CI: confidence interval; HR: hazard ratio; PFS: progression-
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Figure 3. Difference in PFS with Kd56 vs. Vd eight cycles. The difference in PFS for Kd56 vs. Vd eight cycles was estimated using
ENDEAVOR Vd data adjusted for the increased PFS risk associated with stopping Vd after eight cycles. Vd cycle length was
21 days. CI: confidence interval; HR: hazard ratio; Kd56: carfilzomib and dexamethasone; PFS: progression-free survival; Vd: bortezo-
mib and dexamethasone.
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reduction, that is, capturing both the first eight cycles
and the period beyond that, in a single measure, was
56% for Kd56 vs. Vd-8 (HR: 0.44; 95% CI 0.30, 0.66).
Similar results were obtained in scenario analyses.
The excess risk of progression or death associated
with stopping Vd after eight cycles vs. continuing Vd
until progression was estimated to be between 30%
and 41%. The overall risk reduction associated with
Kd56 vs. Vd-8 was estimated to be between 0.43 and
0.45. Table 2 presents an overview of the results of
the scenario analyses.
To assess whether the duration of treatment, in par-
ticular Vd treatment, had an impact on the depth of
response, cumulative rates of CR or better and VGPR
or better observed with Kd56 and Vd (given until pro-
gression) in ENDEAVOR were assessed (Figure 4). Over
the entire treatment period, cumulative rates of both
CR or better and VGPR or better were higher in
patients receiving Kd56 than in those receiving Vd.
During the first eight cycles, rates of CR or better
and VGPR or better increased steadily for patients
receiving Vd and started to become stable during sub-
sequent cycles.
Safety analyses
Crude incidences and exposure-adjusted incidence
rates of TEAEs in patients receiving Kd56 and Vd-8 in
ENDEAVOR are shown in Table 3. Crude incidences
tended to be higher in the Kd56 group than in the
Vd-8 group. However, exposure-adjusted incidences
per 100 person-years were lower with Kd56 than with
Vd-8 for all TEAE categories assessed. Thus, after
adjusting for exposure time, the risks of a grade 3 and
Table 2. Excess risk of progression or death associated with stopping Vd after eight cycles vs. continuous Vd until progression,
and efficacy of Kd56 vs. Vd-8.
Analysis
Excess risk of progression or death associated with
stopping Vd after 8 cycles vs. Vd until progression PFS HR for Kd56 vs. Vd-8
Base case analysisa 32% (–11%, 96%) 0.44 (0.30; 0.66)
Truncated PFS at 16 months 30% (–13%, 94%) 0.45 (0.30; 0.68)
All variables used for matchingb 38% (–8%, 108%) 0.43 (0.29; 0.65)
No matching 41% (–3%, 106%) 0.43 (0.30; 0.61)
HR: hazard ratio; IMID: immunomodulatory imide drugs; Kd56: carfilzomib and dexamethasone; PFS: progression-free survival; PI: proteasome inhibitor;
Vd: bortezomib and dexamethasone; Vd-8: bortezomib and dexamethasone given until eight cycles
aBase case covariates: age (65, 75, other), time from diagnosis, International Staging System (2, 3, other), creatinine clearance (>60mL/min, other),
number of prior therapies (1, 2, other), prior stem cell transplantation (yes, no), prior bortezomib (yes, no), prior IMID (yes, no), refractory to last prior
therapy (yes, no).
bAll available covariates: besides the covariates in the base case analysis, sex (male, female), type of multiple myeloma (IgG, other), prior lenalidomide
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Figure 4. Cumulative rates of patients with a complete response or better or with a very good partial response or better with
Kd56 and Vd in ENDEAVOR. Cumulative rate of CR or better or VGPR or better was assessed from the start of treatment in the
safety population by an independent review committee (Kd: n¼ 463; Vd: n¼ 456). The time at which treatment for Vd eight
cycles would be discontinued (i.e. at 8 21-day cycles) is indicated by a dashed line. CR: complete response; Kd56: carfilzomib
and dexamethasone; Vd: bortezomib and dexamethasone arm; VGPR: very good partial response.
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above or of a serious TEAE were estimated to be
approximately 35% lower with Kd56 than with Vd-8.
The risk of a TEAE leading to discontinuation of any,
or both, study drugs was estimated to be approxi-
mately 60% lower with Kd56 than with Vd-8 (Table 3).
An additional safety analysis assessed specific TEAEs
that had been previously found to be associated with
Kd56 (cardiovascular events) or Vd (peripheral neur-
opathy, gastrointestinal toxicities) [13] (Table 4). The
incidence of grade 2 or above, or grade 3 or above,
peripheral neuropathies was lower in the Kd56 group
than in the Vd-8 group. Likewise, the exposure-
adjusted estimates indicated that rates were higher
with Vd-8 than with Kd56 for diarrhea, nausea, and
constipation. For the cardiovascular TEAEs of cardiac
failure, hypertension, and embolic or thrombotic
events, crude incidences and exposure-adjusted inci-
dence rates per 100 person-years were higher in the
Kd56 group than in the Vd-8 group for all three out-
comes, but these findings were not statistically signifi-
cant. The exposure-adjusted rate ratios were 1.18 (95%
CI 0.66, 21.4), 1.81 (95% CI 1.26, 2.60), and 1.85 (95%
CI 0.97, 3.52) for cardiac failure, hypertension, and
embolic or thrombotic events, respectively.
Discussion
This exploratory analysis of ENDEAVOR that used MAIC
methodology aimed to estimate the difference in effi-
cacy with Kd56 vs. Vd-8. The results suggest that the
benefit for PFS with Kd56 treatment over Vd treat-
ment is larger if Vd is given for eight cycles only
instead of continued until progression. Furthermore,
the data suggest that a prolonged treatment duration
of Vd improves PFS, thus adding to the growing body
of evidence that there may be a benefit for patients
receiving proteasome inhibitor treatment until pro-
gression rather than for a fixed number of cycles.
If Vd had been given for eight cycles, the risk of
progression or death was estimated to be 56% lower
with Kd56 than with Vd-8. This difference in PFS risk is
greater than that observed in the original ENDEAVOR
trial where Vd was administered until progression, and
where the risk of progression or death was 47% lower
with Kd56 than with Vd [13]. Scenario analyses sug-
gested that the results were robust. A corresponding
analysis for OS could not be performed, because sur-
vival data from the CASTOR trial were not as mature
as PFS data at the time of this analysis.
Apart from the estimated difference between Kd56
and Vd-8, the findings of the present study may indi-
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and possibly other proteasome inhibitors, beyond
eight cycles could result in prolonged PFS. With V, it
has been shown that proteasome function recovers
within 72 hours after dosing, with no observed long-
term effects on the proteasome [28,29] indicating that
the efficacy of V could be related to both the duration
of therapy and cumulative dose received. Several
other recently published studies have also demon-
strated that prolonged treatment with proteasome
inhibitors or immunomodulatory drugs provides a
benefit for patients [30–34]. Subcutaneous V, which
has been shown to be as efficacious as intravenous V
but to have a more favorable safety profile [35],
should enable patients to receive longer treatment
with less toxicity. Continuous treatment with prote-
asome inhibitors might lead to a benefit for improved
outcomes, especially in high-risk patients, such as
those with del[17/17p] cytogenic abnormalities [36].
Thus, the identification of patients who can tolerate
continuous treatment with proteasome inhibitors
might be of clinical value in the management of MM.
To identify possible drivers for the improved PFS
benefit with a longer Vd treatment duration, cumulative
response rates were assessed for patients receiving
Kd56 and Vd in ENDEAVOR (both given until progres-
sion). Cumulative rates of CR or better and VGPR or
better were consistently higher with Kd56 than with
Vd, indicative of a greater depth of response with Kd56
than with Vd, an effect that is likely to contribute to
the longer duration PFS with Kd56 than with Vd. In the
Vd arm, rates of CR or better and VGPR or better con-
tinued to gradually increase after cycle 8, which may
imply that the improved PFS with continued Vd treat-
ment beyond eight cycles likely contributes to a greater
depth of response. However, a carryover effect of the
eight cycles administered previously cannot be
excluded. Continued Vd treatment duration might also
provide a benefit for PFS by maintaining the response
achieved during the early cycles, whereas stopping Vd
after eight cycles could increase the risk of relapse. In
line with this hypothesis, in ENDEAVOR the median
(range) duration of response to continued Vd was 10.4
(95% CI 9.3, 13.8), whereas it was 7.9 months (95% CI
6.7, 11.3) with eight cycles of Vd in CASTOR [13,17].
Using truncated data for patients who received
more than eight cycles of Vd in ENDEAVOR the differ-
ences in the safety profiles of Kd56 and Vd given for
eight cycles were estimated. For any TEAE, grade 3 or
higher TEAEs, serious TEAEs, TEAEs leading to discon-
tinuation, and fatal TEAEs, exposure-adjusted incidence
rates were lower with Kd56 than with Vd-8. Consistent
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neuropathy was significantly higher with Vd given for
eight cycles than with Kd56. Hypertension, a known
and manageable side-effect with carfilzomib, was more
frequent with Kd56 than with Vd-8. Cardiac failure and
embolic and thrombotic events were also more fre-
quent with Kd56 than with Vd-8.
Several factors should be considered when interpret-
ing the present data. First, the analysis used MAIC meth-
odology, which is considered less robust than a
randomized controlled trial. Compared with other indir-
ect treatment comparisons such as network meta-analy-
ses that do not adjust for differences in trial design or
patient populations and are thus susceptible to greater
bias, MAIC is a more robust methodology and is consid-
ered more reliable by payers and health technology
assessment authorities to fill any gaps in the available
comparative evidence. Another limitation of the present
study is that the follow-up durations were different
between the ENDEAVOR data (median follow-up:
11.1 months (Vd group) and 11.9 months (Kd56 group))
and the CASTOR data (median follow-up: 19.4 months);
however, this is due to PFS data from the longest pub-
lished follow-up available at the time of the analyses
being included, in order to achieve the most robust
analysis. Moreover, the ENDEAVOR PFS Kaplan–Meier
curves are mature up to about 16–18 months, allowing
a reliable and robust comparison even beyond the first
eight Vd cycles. Finally, patient-level data for Vd-8 had
to be reconstructed, which inherently adds uncertainty
to the reported results.
The methodological approach used in this study
attempted to adjust for the differences in trial design,
notably in this case Vd treatment duration, allowing
cross-trial comparisons to be undertaken. Using this
approach, the analyses suggested that, if Vd had been
given for only eight cycles instead of continued until
progression, the treatment benefit with Kd56 would
have been larger, with lower HR than that observed in
ENDEAVOR. Exposure-adjusted incidence rates of grade
3 or worse TEAEs were lower with Kd56 than with Vd.
Overall, it was concluded that the duration of Vd treat-
ment has a significant impact on both the response
rates and duration of response, and that the relative
efficacy and safety of Kd56 vs. Vd are increased when
Vd treatment is provided as per label guidance.
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